Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

ColoMARK Identification and development of novel colorectal cancer biomarkers via state-of-the-art liquid biopsy approaches

Coordinator
Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela, Spain
Runs
1 November 2022 to 30 April 2027
Status
Running
EU funding
€2.7m
Total cost
—
Partners
16 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072448

What the project is doing

In the project's own words, from its summary on CORDIS.

The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinformatics, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) that will take advantage of the assets conferred by novel liquid biopsy strategies to provide complementary and comprehensive know-how on the features required to successfully fulfil the objectives of ColoMARK: 1) to foster a next generation of scientists that can address the challenges of colorectal cancer biomarker development.

The network is enforced by pre-existing collaborations from COST Action TransColonCan, and enhanced by the participation of non-academic entities, who will play an essential role in the cross-sectoral and transversal training of the researchers. It is our purpose to provide a personalised training programme that builds on the knowledge offered by the participants to produce future cross-sectoral leadership and a sustainable initiative of excellent research that enhances the competitiveness of European researchers; 2) to achieve maximum impact by appropriate dissemination, patient and public engagement, and results exploitation, activities that will be embedded in the training of the researchers.

Given the promising perspectives of liquid biopsy approaches for the future of cancer prevention and management, ColoMARK will constitute an opportunity to reach outstanding scientific, technological and societal impact in a field highly relevant to Horizon Europe´s priorities in cancer, therefore enhancing European competitiveness in R&I; 3) to advance in colorectal cancer understanding by producing outstanding, synergistic research.

As the main scientific aim of ColoMARK, ten tailored ground-breaking research projects, only possible in the context of ColoMARK, will be undertaken for the identification and validation of better risk, prognostic and monitoring colorectal cancer biomarkers.

Topics

Who is involved

OrganisationCityCountryRole
Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De CompostelaSantiago De CompostelaSpainCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyParticipant
Qiagen GmbHHildenGermanyAssociatedpartner
Destina Genomica SlneGranadaSpainParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Servizo Galego De SaudeSantiago De CompostelaSpainAssociatedpartner
Universidad De GranadaGranadaSpainAssociatedpartner
Universidad De Santiago De CompostelaSantiago De CompostelaSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Centre International De Recherche Sur Le CancerLyon 7emeFranceParticipant
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Iigm FoundationTorinoItalyAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
GenomeScan B.V.LeidenNetherlandsParticipant
European Association for Cancer ResearchNottinghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI